4.7 Article

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

期刊

ANNALS OF ONCOLOGY
卷 26, 期 8, 页码 1573-1588

出版社

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv187

关键词

non-small-cell lung cancer; locally advanced; stage III; recommendations; ESMO

类别

资金

  1. Pfizer
  2. Roche
  3. Boehringer Ingelheim
  4. AstraZeneca
  5. Eli-Lilly Chair in Respiratory Oncology at the Leuven University
  6. AstraZeneca Chair in Personalised Lung Cancer Care at the Leuven University
  7. Eli Lilly
  8. Genentech
  9. Lilly
  10. Endocyte
  11. Novartis
  12. Varian Medical Systems
  13. Covidien
  14. ScreenCell
  15. PointHope
  16. Merck Serono
  17. Cancer Research UK [20465] Funding Source: researchfish

向作者/读者索取更多资源

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据